FDA clears Consano Bio's IND for C-1101, enabling U.S. expansion of a potential first-in-class non-opioid therapy for chronic sciatica
Executive summary: Consano Bio received FDA Investigational New Drug (IND) clearance to expand its C-1101 chronic sciatica clinical development program into the United States. This enables U.S. trials for a potential first‑in‑class disease‑modifying non‑opioid therapy addressing a large unmet need in chronic sciatica treatment.
Who is involved: Consano Bio, Inc.; U.S. Food and Drug Administration (FDA); patients with chronic sciatica.
Likely next: Initiation of U.S. clinical sites, dosing of first patients, and subsequent read‑outs of safety and efficacy data.
The IND allows Consano Bio to proceed with U.S. clinical trials for C-1101, a molecule aimed at modifying disease biology rather than just symptom relief. Chronic sciatica affects millions and currently lacks disease-modifying treatments, with patients reliant on opioids or invasive procedures. The clearance signals FDA's willingness to consider novel non‑opioid approaches for neuropathic pain. Success could create a new therapeutic class and affect analgesic market dynamics.
Timeline
- — Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States (PR Newswire)
Analysis — what this means
Likely next events
- Start of U.S. clinical sites for C-1101 Phase 2 trial expected by October 2026.
- First patient dosing in the U.S. trial anticipated in Q4 2026.
- Interim safety data read‑out projected for mid‑2027.
- Potential request for Fast Track or Breakthrough Therapy designation based on early efficacy signals.
Sectors affected
- Neuropathic pain therapeutics
- Non‑opioid analgesics
- Chronic sciatica treatment
Regulatory implications
- FDA IND clearance permits U.S. clinical trials; a future NDA will need to demonstrate disease‑modifying effect.
- The therapy may qualify for expedited pathways (Fast Track, Breakthrough) if preliminary data show substantial improvement over existing options.
Historical parallels
- FDA approval of gabapentin for neuropathic pain (1994).
- FDA approval of duloxetine for diabetic peripheral neuropathy (2004).
- Clinical development of tanezumab for osteoarthritis pain was halted by the FDA in 2010 due to safety concerns.
Key entities
Sources
Related cases
- Karmanos Cancer Institute begins offering the newly FDA‑approved KRAS G12C inhibitor daraxonrasib (Rasonque) for metastatic pancreatic cancer, marking the first clinical rollout of a targeted therapy for a historically hard‑to‑treat malignancy
- FDA clears Caliway's CBL-514 combo with tirzepatide for Phase 2 trial as pivotal Phase 3 SUPREME-01 starts enrollment
- FDA’s approval of IMAAVY provides the first-ever drug for warm autoimmune hemolytic anemia, creating a new niche in rare disease therapeutics
- FDA approves Implantica's RefluxStop, clearing the way for US market entry of a new GERD treatment device
- FDA approval clears the way for Implantica’s RefluxStop to enter the U.S. GERD treatment market
- AbelZeta regains global rights to C‑CAR039 (Prizlon‑cel) and secures FDA IND clearance for large B‑cell lymphoma therapy